Your browser doesn't support javascript.
loading
Global research and learning agenda for building evidence on contraceptive-induced menstrual changes for research, product development, policies, and programs.
Hoppes, Emily; Nwachukwu, Chukwuemeka; Hennegan, Julie; Blithe, Diana L; Cordova-Gomez, Amanda; Critchley, Hilary; Doncel, Gustavo F; Dorflinger, Laneta J; Haddad, Lisa B; Mackenzie, Amelia C L; Maybin, Jacqueline A; Moley, Kelle; Nanda, Kavita; Sales Vieira, Carolina; Vwalika, Bellington; Kibira, Simon P S; Mickler, Alexandria; OlaOlorun, Funmilola M; Polis, Chelsea B; Sommer, Marni; Williams, Katie M; Lathrop, Eva; Mahajan, Tanya; Rademacher, Kate H; Solomon, Marsden; Wilson, Katrina; Wilson, Lucy C; Rountree, Lillian.
Afiliação
  • Hoppes E; FHI 360, Durham, NC, 27701, USA.
  • Nwachukwu C; United States Agency for International Development (USAID), Washington, District of Columbia, 20523, USA.
  • Hennegan J; Maternal Child and Adolescent Health Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Blithe DL; Contraceptive Development Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, 20892, USA.
  • Cordova-Gomez A; United States Agency for International Development (USAID), Washington, District of Columbia, 20523, USA.
  • Critchley H; MRC Centre for Reproductive Health, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, EH8 9YL, UK.
  • Doncel GF; CONRAD, Eastern Virginia Medical School, Norfolk, Virginia, 23507, USA.
  • Dorflinger LJ; FHI 360, Durham, NC, 27701, USA.
  • Haddad LB; Center for Biomedical Research, Population Council, New York, New York, 10017, USA.
  • Mackenzie ACL; FHI 360, Durham, NC, 27701, USA.
  • Maybin JA; MRC Centre for Reproductive Health, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, EH8 9YL, UK.
  • Moley K; Bill & Melinda Gates Foundation, Seattle, Washington, 98109, USA.
  • Nanda K; FHI 360, Durham, NC, 27701, USA.
  • Sales Vieira C; Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of São Paulo, São Paulo, Brazil.
  • Vwalika B; Departments of Obstetrics and Gynaecology, University of Zambia School of Medicine, Lusaka, Zambia.
  • Kibira SPS; Department of Community Health and Behavioural Sciences, School of Public Health, Makerere University, Kampala, Uganda.
  • Mickler A; United States Agency for International Development (USAID), Washington, District of Columbia, 20523, USA.
  • OlaOlorun FM; Department of Community Medicine, University of Ibadan, Ibadan, Nigeria.
  • Polis CB; Independent Researcher, Brooklyn, New York, USA.
  • Sommer M; Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York, 10032, USA.
  • Williams KM; FHI 360, Durham, NC, 27701, USA.
  • Lathrop E; Population Services International, Washington, District of Columbia, 20526, USA.
  • Mahajan T; The Pad Project, New Delhi, India.
  • Rademacher KH; FHI 360, Durham, NC, 27701, USA.
  • Solomon M; FHI 360, Durham, NC, 27701, USA.
  • Wilson K; MSI Reproductive Choices, London, W1T 6LP, UK.
  • Wilson LC; Rising Outcomes, Hillsborough, NC, 27278, USA.
  • Rountree L; FHI 360, Durham, NC, 27701, USA.
Gates Open Res ; 6: 49, 2022.
Article em En | MEDLINE | ID: mdl-35614964
Background: Contraceptive-induced menstrual changes (CIMCs) can affect family planning (FP) users' lives in both positive and negative ways, resulting in both opportunities and consequences. Despite this, and despite the important links between FP and menstrual health (MH), neither field adequately addresses CIMCs, including in research, product development, policies, and programs globally. Methods: In November 2020, a convening of both MH and FP experts reviewed the existing evidence on CIMCs and identified significant gaps in key areas. Results: These gaps led to the establishment of a CIMC Task Force in April 2021 and the development of the Global Research and Learning Agenda: Building Evidence on Contraceptive-Induced Menstrual Changes in Research, Product Development, Policies, and Programs Globally (the CIMC RLA) , which includes four research agendas for (1) measurement, (2) contraceptive research and development (R&D) and biomedical research, (3) social-behavioral and user preferences research, and (4) programmatic research. Conclusions: Guided by the CIMC RLA, researchers, product developers, health care providers, program implementers, advocates, policymakers, and funders are urged to conduct research and implement strategies to address the beneficial and negative effects of CIMCs and support the integration of FP and MH. CIMCs need to be addressed to improve the health and well-being of women, girls, and other people who menstruate and use contraceptives globally. Disclaimer : The views expressed in this article are those of the authors. Publication in Gates Open Research does not imply endorsement by the Gates Foundation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article